

## Abstract

The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP $\alpha$ ), said prodrug is chemically stable under physiological conditions and can be used for the manufacture of physically stable aqueous formulations. It has a cleavage site which is recognised by FAP $\alpha$ , and the drug released by the enzymatic activity of FAP $\alpha$  is cytotoxic or cytostatic under physiological conditions.